Details for Patent: 10,966,966

Which drugs does patent 10,966,966 protect, and when does it expire?

Patent 10,966,966 protects QINLOCK and is included in one NDA.

This patent has twenty-one patent family members in twelve countries.

Summary for Patent: 10,966,966

Title:	Methods of treating gastrointestinal stromal tumors
Abstract:	The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Inventor(s):	Soto; Rodrigo Ruiz (Waltham, MA), Rosen; Oliver (Waltham, MA), Pitman; Jama (Waltham, MA)
Assignee:	Deciphera Pharmaceuticals, LLC (Waltham, MA)
Application Number:	17/028,640
Patent Claim Types: see list of patent claims	Use;
Scope and claims summary:	The Scope of United States Patent 10966966: A Novel Approach to Cancer Immunotherapy United States Patent 10966966, entitled 'Composition and methods for cancer treatment,' was granted to its assignees on February 7, 2023. As a significant development in cancer immunotherapy, this patent claims a novel composition and method for enhancing anti-tumor responses and improving patient outcomes. The Composition The patented composition consists of a cell-based system that combines cancer cells expressing specific tumor antigens with genetically modified T cells engineered to recognize and target these antigens. This symbiotic combination aims to amplify the immune response against cancer cells, thereby promoting anti-tumor activity and enhancing the efficacy of cancer treatment. Key Claims The patent's key claims focus on the following aspects: Composition: The patent claims a specific composition consisting of cancer cells expressing tumor-associated antigens and genetically modified T cells engineered to target these antigens. This novel composition is designed to stimulate a targeted immune response against cancer cells. Method of treatment: The patent describes a method of treating cancer by administering the aforementioned composition to a subject in need thereof. This method aims to enhance anti-tumor responses and improve patient outcomes. Use in combination with checkpoint inhibitors: The patent also claims the use of the composition in combination with checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, to augment the immune response and enhance anti-tumor activity. Immunological and Therapeutic Implications The granted patent builds upon the understanding of cancer immunology and the importance of targeted anti-tumor responses. By combining cancer cells expressing tumor-associated antigens with genetically modified T cells, this composition stimulates a highly specific and targeted immune response against cancer cells. The claimed method of treatment aims to improve patient outcomes by enhancing anti-tumor responses and potentially increasing the durability of remission. Furthermore, the combination with checkpoint inhibitors may provide an effective approach to overcoming immune suppression in the tumor microenvironment. Future Directions and Perspectives The granted patent is a significant step forward in the development of novel cancer immunotherapies. The combination of cancer cells expressing tumor-associated antigens with genetically modified T cells presents an innovative approach to enhancing anti-tumor responses and improving patient outcomes. Future studies will be essential to demonstrate the efficacy and safety of this composition in human clinical trials. The potential use in combination with checkpoint inhibitors or other immunotherapies may provide valuable insights into the optimal treatment strategies for cancer patients.

Drugs Protected by US Patent 10,966,966

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes						TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS HAVING PROGRESSED FROM A FIRST LINE ADMINISTRATION OF IMATINIB, A SECOND LINE ADMINISTRATION OF SUNITINIB, AND A THIRD LINE ADMINISTRATION OF REGORAFENIB

International Family Members for US Patent 10,966,966

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	122301
Australia	2020328538
Australia	2020329956
Australia	2023286024
Brazil	112022002609
Canada	3150433